Albumin-Hitchhiking Lipid Nanoparticles Achieve 80% Liver Accumulation Reduction and 2-3x Lymphatic mRNA Expression

June 28, 2026

ACS Materials Au USA

Overview

A novel lipid nanoparticle (LNP) delivery concept has been developed to overcome the off-target liver accumulation and associated hepatotoxicity of mRNA therapeutics by interacting with endogenous albumin. This new LNP successfully reduced liver accumulation by approximately 80% while simultaneously increasing mRNA expression in lymph nodes by 2 to 3 times. This breakthrough significantly enhances the safety and targeting specificity of mRNA and nucleic acid-based therapies, paving the way for safer and smarter nanomedicine applications.

In Depth

Key Findings

A groundbreaking lipid nanoparticle (LNP) concept has been introduced that leverages interaction with endogenous albumin to circumvent non-specific liver accumulation and enhance lymphatic delivery of mRNA and nucleic acid-based therapeutics. This innovation directly addresses the major clinical challenge of liver toxicity associated with conventional LNPs. The new LNP design has demonstrated an impressive approximately 80% reduction in liver accumulation, alongside a 2- to 3-fold increase in localized mRNA expression within lymph nodes.

Technical / Clinical Details

Traditional LNPs, following intravenous administration, are predominantly cleared by Kupffer cells in the liver, contributing to hepatotoxicity and systemic side effects. The newly developed LNP features a sophisticated surface modification designed to bind strongly with circulating endogenous albumin. Albumin, known for its long half-life and role as a transporter of various substances in the body, acts as a “hitchhiker,” enabling the LNP to avoid direct hepatic uptake and promoting access to the lymphatic system. This mechanism facilitates efficient mRNA expression in lymph nodes, a desirable target for applications such as vaccines and immunotherapies. In mouse models, the research confirmed an approximately 80% suppression of LNP uptake by the liver, coupled with a 2 to 3 times increase in mRNA expression in the lymph nodes compared to conventional LNP formulations.

Background & Context

Since the monumental success of mRNA vaccines during the COVID-19 pandemic, mRNA technology has expanded beyond infectious disease vaccines to encompass broad therapeutic areas, including cancer immunotherapy, gene therapy, and regenerative medicine. However, the inherent instability and poor cellular membrane permeability of mRNA necessitate effective delivery systems like LNPs. While current LNP formulations exhibit high tropism for the liver, optimizing systemic delivery to other organs and tissues while minimizing side effects has been the next frontier. This novel albumin-mediated LNP design presents a paradigm-shifting solution to this critical challenge.

Strategic Significance & Outlook

This innovative LNP delivery strategy holds immense potential to significantly improve the safety profile and expand the therapeutic window of mRNA and nucleic acid-based medicines. It is particularly anticipated to enhance the efficacy of cancer vaccines and autoimmune disease therapeutics that specifically target lymph nodes. Future preclinical and clinical studies will further evaluate the long-term safety and efficacy of this LNP platform, marking a crucial step towards realizing safer and more effective next-generation nanomedicine products. By reducing off-target liver accumulation and enabling precise targeting of immune cells, this technology is also expected to contribute significantly to the advancement of personalized medicine.

Source: https://pubs.acs.org/doi/10.1021/acsmaterialsau.6c00068

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.